- About PRA
Since our inception in 1976, PRA has amassed a level of expertise that has enabled us to conduct complex global clinical trials across all therapeutic areas and provide outsourced clinical services across all phases of pharmaceutical and biotech drug development.
View a timeline of PRA's history.
This page will show you a map of all PRA locations and allow you to select the regions for details on our office locations.
Mission and Values
Our Mission: Our people commit to provide innovative solutions that our clients rely upon to introduce new drugs and to improve lives. Our Vision: We shall build a legacy of quality and trust.
PRA makes its financial information and reports available to holders of our Senior Notes and to any beneficial owners of the Senior Notes, as well as any prospective investors, securities analysts or market makers. The information is posted in a password-protected online data system and requires a signed eligibility letter.
PRA’s Therapeutic Expertise group is a scientific and medical expertise resource offered by PRA to provide clinical development support.
PRA has three fully equipped and harmonized bioanalytical laboratories: small and large molecule laboratories in Europe (Assen, The Netherlands) as well as a small molecule facility based in the United States (Lenexa, Kansas). Both the US and EU laboratories are situated close to our clinics to facilitate studies producing time-sensitive samples. The Lenexa facility first came on-line in October 2010, and is fully equipped with state-of-the-art bioanalytical instrumentation to provide expertise and security for your clinical samples. The Assen locations have been active since the mid-1980s to support our Phase I Clinics in Zuidlaren and Groningen and provide a benchmark for the quality of our laboratory services.
PRA's clinical facilities in The Netherlands, the United States and Central and Eastern Europe (CEE) provide 260 beds worldwide including, our specialized Unit on Demand model in CEE. PRA’s harmonized laboratory facilities in The Netherlands and the US are situated close to the clinical facilities and are configured to fully support all clinical study requirements. Our clinics are fully equipped with the technology and infrastructure required for high quality, efficient studies across a range of drugs and indications.
PRA is transforming clinical trials through our people, innovation and transparency. We have achieved a level of expertise that enables us to work across a range of compounds, from niche treatments to blockbuster drugs and biosimilars. Our Product Registration group executes complex, global Phase II-III studies for a variety of indications.
- Biostatistics and Medical Writing
- Clinical Operations
- Data Management
- Data Capture
- Data Transparency
- Data Integration
- Investigator Relations Group
- Medical Affairs
- Patient Recruitment and Retention
- Project Management
- Quality Assurance
- Regulatory Affairs
- Marketing Application Submission Services
- Investigator and Site Engagement Program
Late Phase Services:
PRA is a global expert in the design, management and implementation of post-marketing and minimal risk studies for pharmaceutical, biotech and medical device companies. Our late-phase infrastructure is designed to support your studies throughout the proving process, providing you with a dedicated, effective and knowledgeable partner to smooth the way.
Safety & Risk Management
Minimization of risk to patients has always been a top line priority in the context of new medicinal product development. Regulatory authorities now, more than ever, emphasize the importance of appropriate safety management infrastructure. The development of risk minimization strategies suitable for the whole life cycle of the medicinal product is imperative.
Markets & Strategies
PRA provides customized alternative monitoring services aligned with the FDA Clinical Trials Transformation Initiative’s and the EMA’s recommendations.
News - Press Releases24 September 2013 - PRA and RPS Merger Completed 11 September 2013 - PRA Holdings Announces - Proposed Private Offering of $375 Million Senior Notes Due 2023 31 July 2013 - PRA & RPS to Join & Create Leading CRO with Expanded Service Offerings & Capabilities 16 July 2013 - WuXiPRA Names James Pusey President and General Manager 24 June 2013 - Genstar Announces Sale of PRA 24 June 2013 - KKR to Acquire PRA International 8 May 2013 - PRA Supports Welsh Economy with Opening of New Facility in Swansea 17 April 2013 - PRA Program Creates Clinical Research Jobs for New Graduates 25 March 2013 - PRA Voted "Best CRO" in Asia 4 March 2013 - PRA Acquires ClinStar 26 February 2013 - PRA Experts to Speak at Biosimilars & Biologics Conference 4 February 2013 - PRA Experts to Present at Summit for Clinical Operations Executives 29 January 2013 - PRA Nominated for 'Best CRO' Award in Global Contest 18 December 2012 - PRA and WuXi PharmaTech Form Joint Venture 5 December 2012 - PRA Expert to Speak at Late Phase Conference 28 November 2012 - PRA Biosimilars Leader to Speak at Forum 21 November 2012 - PRA Safety Expert Presents at Conference 20 November 2012 - PRA Early Phase Expert Speaks at Bioanalysis Conference 13 November 2012 - PRA Named ‘Clinical Company of the Year’ in National Contest 22 October 2012 - PRA Drug Development Expert to Speak at Conference 10 October 2012 - PRA Hires Product Registration Executive 21 September 2012 - PRA Drug Safety Leader to Present at Conference 20 September 2012 - PRA Late Phase Expert to Present at Conference 22 August 2012 - PRA Expands Operations in China 24 July 2012 - PRA Participates in Landmark Alzheimer’s Prevention Clinical Trial 26 June 2012 - PRA Biosimilars Expert to Speak at Summit 22 June 2012 - PRA Expert to Speak at Best of ASCO Annual Meeting 20 June 2012 - PRA Experts to Present at DIA Annual Conference 26 April 2012 - PRA Announces Strategic Relationship with Amgen 21 May 2012 - PRA Drug Development Expert to Speak at Conference